Chemotherapy comparison for HIV-related Kaposi sarcoma
Treatments studied
Part of Cancer, Immune system & allergy, Infections clinical trials.
This trial compares two chemotherapy drugs, paclitaxel and pegylated liposomal doxorubicin, to see which works better for HIV-related Kaposi sarcoma. It aims to find a more effective treatment to shrink skin lesions and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be HIV-positive.
- You must have Kaposi sarcoma, confirmed by a biopsy.
- Your Kaposi sarcoma must be either advanced (T1) or not improving after at least 12 weeks of HIV treatment.
- You must be at least 18 years old.
- You must be generally active and able to care for yourself (Karnofsky score of 60 or higher).
- Your heart function must be normal (ejection fraction of 50% or higher).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests PDS01ADC, a targeted cancer drug, for advanced Kaposi sarcoma (KS). It also studies how well the drug works when added to the immunotherapy M7824, especially if KS has not responded to prior treatments.
This trial tests an experimental drug (CYT107) that boosts the immune system to help fight Kaposi sarcoma in people with HIV who have a low CD4 count despite good HIV treatment. It aims to see if the drug can improve KS tumors and quality of life.
This Phase 1/2 study tests the medicine abemaciclib to shrink Kaposi sarcoma (KS) lesions and control the disease. It includes both people with HIV and people without HIV, and may help when KS has not responded well to prior treatment or when certain KS stages are present.
This trial tests a new drug called nirogacestat to see if it can shrink Kaposi sarcoma lesions. It is for people with Kaposi sarcoma that has not improved with standard treatment or who cannot tolerate standard treatment.
This trial tests whether propranolol, a beta-blocker medicine, can treat Kaposi sarcoma (KS), a type of cancer that causes lesions on the skin or mouth. It may help people with mild-to-moderate KS, including those with HIV, if their disease has not improved or has worsened despite other treatments.
This study follows people with Kaposi sarcoma to learn more about the disease and how it changes over time. It may help doctors better understand and treat KS in the future.
Hear when a new Kaposi Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.